Metraipolis › archive › dc_e8237fbcf60a

Targeting Metabolic Dysfunction in Parkinson's Disease: The Role of GLP-1 Agonists in Body Weight Regulation and Neuroprotection — Europe PMC PMID:41003884

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41003884
DOI: 10.1007/s11892-[numero omesso]-1
License (as archived): solo-consultazione
Archived: 2026-11-09T18:06:29.783Z
SHA-256 of the archived text: 147e581d2a49cfa5005c7a0ec2564a7ba2cb9e789eeef7a70081ee88f7c47ac7
Stable URL of this page: https://metraipolis.com/documento/dc_e8237fbcf60a

How to cite

Targeting Metabolic Dysfunction in Parkinson's Disease: The Role of GLP-1 Agonists in Body Weight Regulation and Neuroprotection — Europe PMC PMID:41003884 — Europe PMC (en), https://europepmc.org/article/MED/41003884 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e8237fbcf60a (Metraipolis archive dc_e8237fbcf60a, sha256 147e581d2a49cfa5005c7a0ec2564a7ba2cb9e789eeef7a70081ee88f7c47ac7)

BibTeX

@misc{dce8237fbcf60a,
  title = {Targeting Metabolic Dysfunction in Parkinson's Disease: The Role of GLP-1 Agonists in Body Weight Regulation and Neuroprotection — Europe PMC PMID:41003884},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41003884},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e8237fbcf60a; sha256 147e581d2a49cfa5005c7a0ec2564a7ba2cb9e789eeef7a70081ee88f7c47ac7},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41003884. Agents can read the archived copy with the MCP tool read_document.